Project Grant R41EY039188
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $292K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Eye Institute awarded The Schepens Eye Research Institute $858,394 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop multimodal foundation models for eye disease screening and prognosis. The research develops a vision-language foundation model trained on pairs of retinal images and clinical notes to enable downstream supervised models for detection and progression prediction of age-related macular degeneration, diabetic retinopathy, and glaucoma. The...
- F Square Medical LLC received a $880,668 Project Grant from the National Eye Institute of the National Institutes of Health, Department of Health and Human Services under the Vision Research federal grant program (CFDA 93.867) for the period of September 1, 2021 through August 31, 2022. The funding will support F Square Medical's development of the first-ever safe and effective anterior chamber paracentesis instrument to treat and diagnose ocular diseases. Specifically, the company will refine...
- The National Eye Institute awarded $753,787 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop low-cost ultra-widefield retinal optical coherence tomography (OCT) technology based on photonic-electronic integration. The project addresses cost barriers that limit clinical availability of OCT instrumentation used to detect and monitor diabetic retinopathy, age-related macular...
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $439,174 to the Regents of the University of Minnesota on September 1, 2026, under the Vision Research program (CFDA 93.867) to conduct the first study quantifying how autonomous artificial intelligence diagnostic systems expand access to diabetic retinopathy screening and treatment. The project will use 100% of Medicare claims data to identify adoption of FDA-approved...
- The National Eye Institute awarded Perzeption Inc. $305,406 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and evaluate an efficient photostress recovery assessment method for age-related macular degeneration. The project addresses the need for sensitive functional biomarkers to detect early-stage AMD and measure disease progression or treatment response. Perzeption will develop a novel, personalized, adaptive testing method to assess photostress recovery in...
- The National Eye Institute awarded Neovascularx, Inc. $305,321 on September 30, 2025, under the Vision Research program (CFDA 93.867) to clinically develop and commercialize topical ophthalmic products for treating neovascular age-related macular degeneration (NAMD). The project focuses on developing a home-based topical treatment alternative to existing monthly or bimonthly intravitreous injections of VEGF inhibitors. Current injectable therapies, while effective, present significant challenges...
- The National Eye Institute awarded Nanoscope Instruments, Inc., $1,019,678 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and validate the Multi-Luminance Shape Discrimination Test, a device that measures functional vision in patients with moderate to severe vision loss. The recipient will evaluate the retest variability and performance of the Multi-Luminance Shape Discrimination Test in patients with geographic atrophy, wet age-related macular degeneration,...
- Federal Project Grant Award Summary Kineolabs, Inc. received a $300,001 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to develop a portable, low-cost line-scan swept-source optical coherence tomography imaging system (LS-SS-OCT). The system is designed for early detection and monitoring of age-related macular degeneration (AMD), diabetic retinopathy, and other eye diseases. The one-year project, which commenced July 1, 2025 and concludes June...
- The National Eye Institute awarded Synvivo Inc. $290,400 on September 15, 2026, under the Vision Research program (CFDA 93.867) to develop the first standardized, commercial retinal barrier-on-chip using donor-matched human primary retinal pigment epithelial and choroidal endothelial cells for age-related macular degeneration (AMD) therapeutic testing. Synvivo will design and fabricate a retinal barrier-on-chip in a 3-plex array configuration integrating human choroidal endothelial cells...
- The National Eye Institute awarded The Leland Stanford Junior University $3,573,304 under the Vision Research program (CFDA 93.867) on September 15, 2025, to apply the TEMPO proteomic platform using human liquid biopsy samples to identify protein biomarker signatures and cells driving diabetic retinopathy stages and diabetic macular edema in living patients, and to determine the role of accelerated molecular aging in diabetic retinopathy using a proteomic clock. The TEMPO method integrates...